PTGER2 and ovarian carcinoma: m6A modification of prostaglandin E receptor 2 (PTGER2) is upregulated in ovarian cancer; this is associated with self‐renewal and DNA damage repair capabilities in cancer cells leading to resistance to therapy.[111]